Company: PRME
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001628280-25-050422
Chunk: 76

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 8
Chunk 76
---
 The Second Letter Agreement, among other things, modifies certain development milestones and related payment obligations under the BMS Collaboration Agreement. Except as expressly stated in the Second Letter Agreement, all other terms and provisions of the Broad-Prime License Agreement shall remain in full force and effect.

10.Net Loss per Share 

Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:Three Months EndedSeptember 30,Nine Months EndedSeptember 30,(in thousands, except share and per share amounts)2025202420252024Numerator:Net loss attributable to common stockholders$(50,582)$(52,518)$(155,063)$(153,606)Denominator:Weighted-average common shares outstanding, basic and diluted160,503,183 119,764,270 139,244,743 114,492,416 Net loss per share attributable to common stockholders, basic and diluted$(0.32)$(0.44)$(1.11)$(1.34)Diluted net loss per share available to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, preferred stock, unvested restricted stock awards and stock options to purchase common stock were considered common stock equivalents but had been excluded from the calculation of diluted net loss per share available to common stockholders as their effect was anti-dilutive. In periods in which the Company reports a net loss available to common stockholders, diluted net loss per share available to common stockholders is the same as basic net loss per share available to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:As of September 30,20252024Anti-dilutive common stock equivalents:Options to purchase common stock16,393,177 12,061,612 Unvested restricted common stock awards3,472,546 3,565,262 Total anti-dilutive common stock equivalents:19,865,723 15,626,874 

24

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and